ArticleBreast cancer research : BCR2012
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
Article in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis.Breast cancer (Tokyo, Japan) · 2026Pooled it
- Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.Scientific reports · 2023Trial
- Machine learning-based prediction of breast cancer growth rate in vivo.British journal of cancer · 2019Trial
- Interobserver concordance of tumor-infiltrating lymphocyte assessment in triple-negative breast carcinoma; tissue microarray versus whole sections.CytoJournal · 2025Article
- Artificial intelligence in breast cancer diagnosis: A systematic literature review.Cambridge prisms. Precision medicine · 2025Review
- Prediction of gene expression-based breast cancer proliferation scores from histopathology whole slide images using deep learning.BMC cancer · 2024Article
- Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer.BJC reports · 2024Article
- A retrospective analysis of clinicopathological characteristics and risk factors for recurrence in young patients with breast cancer.Gland surgery · 2024Article
- Prognostic predictive value of Ki-67 in stage I-II triple-negative breast cancer.Future science OA · 2024Article
- Mammary mucinous cystadenocarcinoma with long-term follow-up: molecular information and literature review.Diagnostic pathology · 2023Review
- The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.Cancers · 2023Review
- The characteristics and clinical significance of atypical mitosis in breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Defining the area of mitoses counting in invasive breast cancer using whole slide image.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Ki-67 proliferation index to further stratify invasive breast cancer molecular subtypes: Northern African comparative cohort-study with external TCGA-BRCA and METABRIC validation.The Pan African medical journal · 2022Article
- Expression of LGR5 in mammary myoepithelial cells and in triple-negative breast cancers.Scientific reports · 2021Article
- Review
- Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.Surgical pathology clinics · 2021Review
- Article
- T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.Gland surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAlthough the prognostic significance of proliferation in early invasive breast cancer has been recognized for a long time, recent gene-expression profiling studies have reemphasized its biologic and prognostic value and the potential application of its assessment in routine practice, particularly to define prognostic subgroups of luminal/hormone receptor-positive (HR+) tumors. This study aimed to assess the prognostic value of a proliferation assay by using Ki-67 immunohistochemistry as compared with mitotic count scores.
methodProliferation was assessed by using Ki-67 labeling index (Ki-67LI) and mitotic scores in a large (n = 1,550) and well-characterized series of clinically annotated primary operable invasive breast cancer with long-term follow-up. Tumors were phenotyped based on their IHC profiles into luminal/HR+, HER2+, and triple-negative (TN) classes. We used a split-sample development and validation approach to determine the optimal Ki-67LI cut-offs.
resultsThe optimal cut-points of Ki-67LI were 10% and 50% for the luminal class. Both Ki7LI and MS were able to split luminal tumors into subgroups with significantly variable outcomes, independent of other variables. Neither mitotic count scores nor Ki-67LI was associated with outcome in the HER2+ or the TN classes.
conclusionsAssessment of proliferation by using Ki-67LI and MS can distinguish subgroups of patients within luminal/hormone receptor-positive breast cancer significantly different in clinical outcomes. Overall, both Ki-67 LI and mitotic-count scores showed comparable results. The method described could provide a cost-effective method for prognostic subclassification of luminal/hormone receptor-positive breast cancer in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.